ClinicalTrials.gg
CompletedNCT06998589Updated May 31, 2025

Comparison of the Efficacy and Safety of Delicate Pulsed Light and Q-Switched 1064 nm Nd:YAG Laser in the Treatment of Post-Acne Erythema

An interventional study of DPL in Post-acne Erythema, sponsored by Second Affiliated Hospital of Xi'an Jiaotong University. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-05-31.

Sponsored by Second Affiliated Hospital of Xi'an Jiaotong University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jan 2025, registered May 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Acne vulgaris is a common chronic dermatological condition, affecting approximately 85% of adolescents worldwide and ranking eighth among all chronic diseases. Its exacerbation is often associated with recurrent lesions, inadequate treatment, and poor skincare habits such as squeezing or scratching, which frequently lead to the development of post-acne erythema (PAE). PAE is a vascular lesion located beneath the surface of the skin, characterized by a red appearance due to the clustering of dilated capillaries. Although PAE typically improves within 2 to 6 months, it may persist longer in some cases and even result in post-inflammatory hyperpigmentation. This is particularly prevalent in individuals with darker skin tones, where the incidence of PAE and hyperpigmentation ranges from approximately 45.5% to 87.2%. Facial acne not only affects physical appearance but also significantly impairs social interactions and can lead to psychological distress, including low self-esteem and depression.

Low-energy, large-spot 1064 nm Nd:YAG laser, which belongs to the near-infrared spectrum, has deeper skin penetration and can effectively target deeper dermal tissues. In the treatment of PAE, the laser energy is absorbed by dilated microvasculature in the skin, promoting vasoconstriction and reducing localized redness and swelling. The low energy setting minimizes thermal damage while stimulating collagen production, thereby enhancing skin repair and improving the appearance of erythema.

Delicate Pulsed Light (DPL) operates by emitting pulses of light at specific wavelengths that selectively target skin chromophores. In treating PAE, DPL precisely controls the wavelength and pulse intensity to target dilated blood vessels, thereby alleviating redness and inflammation. Additionally, DPL stimulates the skin's natural repair mechanisms and promotes collagen synthesis, accelerating the resolution of erythema and enhancing overall skin texture. Compared with conventional Intense Pulsed Light (IPL), DPL offers more accurate light modulation, fewer side effects, and better adaptability to various skin types and conditions.

In this study, we conducted a split-face randomized controlled trial to compare the clinical efficacy and safety of low-energy large-spot 1064 nm Nd:YAG laser and DPL in treating acne and PAE. We aimed to explore whether there are significant differences between these two modalities in terms of clinical outcomes for post-acne erythema.

Read the detailed description

Acne vulgaris is a highly prevalent chronic inflammatory skin disease, affecting approximately 85% of adolescents globally, and ranking eighth among all chronic conditions in terms of global disease burden. Although traditionally perceived as a benign and self-limiting disorder, its impact on quality of life, especially when accompanied by persistent post-lesional sequelae such as post-acne erythema (PAE), is increasingly recognized. The aggravation of acne is often multifactorial, closely linked to recurrent inflammatory episodes, inadequate therapeutic interventions, and improper skincare behaviors such as manual squeezing or scratching of lesions. These factors not only exacerbate active lesions but also contribute significantly to the development and persistence of PAE.

PAE is a vascular response resulting from the dilation and proliferation of superficial dermal capillaries following inflammatory acne lesions. It presents clinically as well-demarcated erythematous macules or patches, primarily located on previously inflamed sites. Although PAE can spontaneously resolve within 2 to 6 months, in many individuals-particularly those with darker Fitzpatrick skin types-it may persist significantly longer, often overlapping with post-inflammatory hyperpigmentation (PIH). Epidemiological data suggest that the incidence of PAE and PIH in darker-skinned populations ranges from 45.5% to as high as 87.2%, highlighting the need for effective interventions. Given that acne and its sequelae predominantly involve facial skin, the psychosocial burden is substantial. Patients often experience reduced self-esteem, social withdrawal, and even symptoms of anxiety and depression, underscoring the importance of timely and effective treatment strategies.

Among current therapeutic approaches, low-energy, large-spot 1064 nm Q-switched Nd:YAG laser has garnered attention due to its favorable safety profile and ability to penetrate deeper dermal layers. Operating in the near-infrared spectrum, the 1064 nm wavelength is selectively absorbed by hemoglobin in dilated capillaries, promoting vasoconstriction and diminishing visible erythema. At low energy densities, this laser minimizes thermal injury to surrounding tissues while simultaneously stimulating neocollagenesis, thereby contributing to both vascular remodeling and dermal regeneration. This dual mechanism supports its utility in managing PAE with minimal downtime.

In contrast, Delicate Pulsed Light (DPL), an advanced form of filtered intense pulsed light (IPL), offers enhanced precision through narrower wavelength bands, typically within the 500-650 nm range. This allows for more selective targeting of hemoglobin and melanin, improving therapeutic outcomes while reducing the risk of non-specific tissue damage. In the context of PAE, DPL effectively targets superficial vascular lesions, mitigates inflammatory processes, and promotes skin healing through controlled photothermal effects and collagen stimulation. Compared to conventional IPL, DPL provides improved treatment accuracy, reduced adverse effects, and better adaptability across a range of skin phototypes.

Given the growing demand for non-invasive, effective, and safe interventions for PAE, comparative studies on commonly used energy-based devices are warranted. Therefore, in this study, we conducted a prospective, split-face, randomized controlled trial to compare the clinical efficacy and safety of low-energy 1064 nm Nd:YAG laser and DPL in the treatment of acne and PAE. This design allows for intra-individual comparison, thereby minimizing confounding variables and enhancing the validity of outcome assessments. Our primary objective was to determine whether there are significant differences in the therapeutic outcomes between these two modalities, with a particular focus on erythema resolution, patient satisfaction, and adverse event profiles.

02

Conditions studied

  • Post-acne Erythema

Browse trials for

Keywords

  • post-acne erythema
03

In context

Erythema

131 studies on the registry are indexed under Erythema; 17 are open to participants now.

This study's enrollment of 26 is below the median of 50 across 114 interventional studies indexed under Erythema.

Browse Erythema studies →

Lead sponsor

Second Affiliated Hospital of Xi'an Jiaotong University is the lead sponsor of 70 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 60 years, regardless of gender;
  • Clinically and dermatoscopically diagnosed with acne and post-acne erythema (PAE) with bilaterally symmetrical facial lesions;
  • Patients with normal cognitive function and stable mental status;
  • Patients with good communication abilities;
  • Voluntary participation in the study with signed .

Exclusion criteria

Exclusion Criteria:

  • Patients meeting any of the following conditions will be excluded from the study:
  • History of photosensitivity;
  • Presence of severe immunological disorders;
  • Keloid or hypertrophic scarring tendency;
  • Pregnant or breastfeeding individuals;
  • Alcohol abuse;
  • Presence of other facial skin diseases;
  • Mental illness or psychiatric disorders that impair compliance;
  • Currently pregnant or lactating;
  • Presence of severe internal medical conditions;
  • Poor treatment compliance or inability to cooperate due to psychiatric conditions.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    DPL

    The DPL treatment was randomly applied to one side of the face, with an energy density of 6-8 J/cm². Sessions were performed at intervals of 2-3 weeks, for a total of six treatments.

    Other: DPL

  • Experimental
    Q-switched 1064 nm Nd:YAG laser

    The randomly assigned half of the face received large-spot, low-energy 1064 nm laser treatment at an energy density of 0.8-1 J/cm², performed at intervals of 2-3 weeks for a total of six sessions.

    Other: DPL

Interventions

  • OtherDPL

    The DPL treatment was randomly applied to one side of the face, with an energy density of 6-8 J/cm². Sessions were performed at intervals of 2-3 weeks, for a total of six treatments..The randomly assigned half of the face received large-spot, low-energy 1064 nm laser treatment at an energy density of 0.8-1 J/cm², performed at intervals of 2-3 weeks for a total of six sessions.

06

What researchers measure

Primary outcomes

  1. PAE lesion count

    The post-acne erythema (PAE) lesion count is an important objective indicator for assessing the severity of PAE. It involves recording the number of erythematous lesions on the face to evaluate changes before and after treatment. A higher lesion count indicates more severe erythema and poorer skin recovery. The assessment is typically conducted independently by two trained dermatologists under standardized lighting conditions, with high-resolution imaging systems used when necessary to enhance accuracy and consistency. Care is taken to distinguish PAE from other cutaneous manifestations such as active acne, post-inflammatory hyperpigmentation, and scarring. As a quantitative measure of erythema severity and improvement, the lesion count is widely applied in clinical studies involving light-based and laser therapies.

    Time frame: 0, 4, 8, 12 weeks

Secondary outcomes

  1. CEA score

    The CEA score can be used to estimate the overall severity of the patient's condition. The score ranges from 0 to 4, with higher scores indicating more severe conditions.

    Time frame: 0, 4, 8, 12 weeks

  2. erythema index

    Use non-invasive skin analyzer to measure the erythema index on the patient's facial skin at each follow-up visit.The larger the value, the more severe the erythema.

    Time frame: 0, 4, 8, 12 weeks

  3. GFSS score

    The name of the scale is Global Flushing Severity Scale. The score ranges from 0 to 4, with higher scores indicating more severe conditions.

    Time frame: 0, 4, 8, 12 weeks

07

Study locations

1 site
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, 710004, China
08

References and documents

Publications

  • Wu X, Wang X, Wu X, Cen Q, Xi W, Shang Y, Zhang Z, Lin X. Intense Pulsed Light Therapy Improves Acne-Induced Post-inflammatory Erythema and Hyperpigmentation: A Retrospective Study in Chinese Patients. Dermatol Ther (Heidelb). 2022 May;12(5):1147-1156. doi: 10.1007/s13555-022-00719-9. Epub 2022 Apr 12. PubMed 35415801 ↗
  • Urban K, Chu S, Giesey RL, Mehrmal S, Uppal P, Delost ME, Delost GR. Burden of skin disease and associated socioeconomic status in Asia: A cross-sectional analysis from the Global Burden of Disease Study 1990-2017. JAAD Int. 2020 Dec 10;2:40-50. doi: 10.1016/j.jdin.2020.10.006. eCollection 2021 Mar. PubMed 34409353 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in May 2025, 4 months.

Of 23 non-industry interventional studies with no phase under Erythema, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's 4 months is below that.

Counting every sponsor, half of 43 studies reached it within 3 months; a quarter within 1 and three quarters within 11.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2025
First posted
May 31, 2025
StartActual
Jan 17, 2025
Primary completionActual
May 20, 2025
CompletionActual
May 20, 2025
Last update
May 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06998589
Lead sponsor
Second Affiliated Hospital of Xi'an Jiaotong University
Responsible party
Weihui Zeng (Professor, Second Affiliated Hospital of Xi'an Jiaotong University) — Principal investigator
First posted
May 31, 2025
Start date
Jan 17, 2025
Primary completion
May 20, 2025
Completion
May 20, 2025
Last update
May 31, 2025

Study contacts

Weihui zeng
study chair · Second Affiliated Hospital of Xi'an Jiaotong University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion